Spark's price for Luxturna blindness gene therapy too high: ICER

(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news